Strategic partnerships Exegenesis Bio is actively engaging in collaborations to advance MDL-201 for Duchenne muscular dystrophy with Modalis Therapeutics, signaling openness to co-development and licensing deals that could broaden market access and accelerate pipeline commercialization.

Clinical stage focus With two programs in the clinic targeting CNS and ocular diseases and a robust manufacturing footprint for viral vectors, there are clear opportunities to cross-sell platform capabilities, CAPEX-ready manufacturing services, and early-access programs to potential partners and CROs working in gene therapy.

Geographic reach Operations spanning the United States and China with a presence in Boston, Philadelphia, and China create pathways for multinational collaborations, regional manufacturing partnerships, and regulatory enablement services that can appeal to global sponsors seeking dual-market strategies.

Capability leverage Proprietary capsids, promoters, and protein designs paired with state-of-the-art cGMP facilities position Exegenesis Bio to offer advanced vector development, process development, and scalable manufacturing for partners aiming to de-risk and accelerate gene therapy programs.

Financial and momentum signals Significant fundraising and ongoing high-profile conference presence (ASGCT) indicate strong growth trajectory and visibility, presenting opportunities to engage for strategic investments, milestone-driven collaborations, and joint visibility in future therapies and platform enhancements.